456
Participants
Start Date
March 25, 2024
Primary Completion Date
May 1, 2026
Study Completion Date
May 1, 2026
SP-624
Once daily oral administration of two capsules totaling 20 mg/day
Placebo
Once daily oral administration of two matching placebo capsules
Pioneer Clinical Research, New York
Integrative Clinical Trials, Brooklyn
Magnolia Clinical Research, Cary
UNC Chapel Hill, Chapel Hill
New Hope Clinical Research, Charlotte
Coastal Carolina Research Center, North Charleston
Accelerated Enrollment Solutions, Atlanta
Clinical Neuroscience Solutions, Jacksonville
Clinical Neuroscience Solutions, Orlando
Segal Trials - Miami Lakes, Miami Lakes
Segal Trials, Lauderhill
DMI Research, Pinellas Park
Accel Clinical, Lakeland
Clinical Neuroscience Solutions, Memphis
Velocity Clinical Research, Beachwood
North Star Medical Research, Middleburg Heights
Midwest Clinical Research Center, Dayton
Revive Research Institute, Elgin
Alivation Research, Lincoln
Tandem Clinical Research, Marrero
SanRo Clinical Research Group, Bryant
Pillar Clinical Research, Richardson
Future Search Trials of Dallas, Dallas
Grayline Research Center, Wichita Falls
R and H Clinical Research, Stafford
Donald J. Garcia, Jr, MD, PA, Austin
Haracec Clinical Research, El Paso
MCB Clinical Research Centers, Colorado Springs
Velocity Clinical Research, Meridian
IMA Clinical Research, Phoenix
Noble Clinical Research, Tucson
IMA Clinical Research, Albuquerque
IMA Clinical Research, Las Vegas
Redbird Research, Las Vegas
Collaborative Neuroscience Research, Torrance
Clinical Innovations, Bellflower
Next Level Clinical Trials, West Covina
Synergy San Diego, Lemon Grove
Excell Research, Oceanside
Sun Valley Research Center, Imperial
CiTrials, Riverside
Sunwise Clinical Research, Lafayette
Summit Headlands, Portland
Northwest Clinical Research Center, Bellevue
Core Clinical Research, Everett
Boston Clinical Trials, Boston
Center for Emotional Fitness, Cherry Hill
CenExel HRI, Marlton
Rho, Inc.
INDUSTRY
Sirtsei Pharmaceuticals, Inc.
INDUSTRY